Several anaplastic lymphoma kinase (ALK) inhibitors have been approved for the treatment of metastatic ALK-positive nonsmall cell lung cancer (NSCLC), including alectinib, crizotinib, brigatinib, ceritinib, and lorlatinib. While efficacy and safety are well documented, real-world data on the use of ALK inhibitors are currently limited. In this pooled analysis of 3 US insurance claims databases, alectinib was associated with longer real-world persistence than other ALK inhibitors, despite similar adherence. This is the first study to assess adherence and persistence with ALK inhibitors for the treatment of patients with ALK-positive NSCLC in real-world clinical practice. READ ARTICLE
Journal of Managed Care and Specialty Pharmacy DOI:10.18553/jmcp.2021.21310
Authors: Apar Kishor Ganti, Chia-Wei Lin, Erru Yang, William B Wong, and Sarika Ogale